Article

Physician-Patient Collaboration Best Way to Evaluate Systemic Sclerosis?

Patients who have systemic sclerosis and their physicians rate disease severity differently in magnitude and are influenced by different factors.

Patients who have systemic sclerosis (SSc) and their physicians rate disease severity differently in magnitude and are influenced by different factors. Therefore, patient-assessed and physician-assessed measures of severity should be considered as complementary.

Hudson and associates compared physician and patient assessment of SSc severity in 803 patients from the Canadian Scleroderma Research Group Registry. Participants numerically rated the following parameters of disease severity: skin involvement, Raynaud phenomenon (RP), dyspnea, GI symptoms, number of fingertip ulcers, tender and swollen joints, and fatigue.

Patients and physicians agreed only modestly about disease severity; patients rated themselves as sicker. Interphysician variability accounted for only a small part of the differences in assessments. The relative importance of parameters also differed-physicians and patients rated skin involvement and pain, respectively, as more important severity indicators. Overall, patients were most influenced by subjective symptoms; significant predictors of patient assessments included severity of RP, GI symptoms, and fatigue. Physicians were affected by such objective measures as disease duration, with early disease being considered worse, and creatinine levels.

On the basis of their findings, the authors recommended collaboration between physicians and patients in the evaluation of SSc severity.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.